The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View aml content recommended for you

EHA2022 abstracts: What's hot in AML?

By Claire Aukim-Hastie,Megan Lee,Ella Dixon

Jun 6, 2022

To help navigate the exciting content being presented at the EHA2022 Congress, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML.

Patient selection for HSCT

P522	Absolute lymphocyte count is an independent survival predictor in patients with acute myeloid leukemia treated with intensive chemotherapy
S167	Prediction of relapse after allogeneic stem cell transplantation using individualized measurable residual disease markers; the prospective nordic study NMDSG14B
S238	Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT

Induction therapy

P103-2	Toward combinations: double and triple therapies
P581	Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials
S125	10-day decitabine vs. conventional chemotherapy ('3+7') followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase II study of the EORTC leukemia group, GIMEMA, CELG, and GMDS-SG
S126	Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Results from the NCRI AML19 'MIDOTARG' pilot trial
S128	A randomised comparison of CPX-351 and FLAG-IDA in high risk acute myeloid leukaemia. Results from the NCRI AML19 trial

Biomarkers and prediction of response

P406	Enhanced significance of FLT3-ITD residual disease detection on treatment outcome in acute myeloid leukemia
P410	LPIN1 regulates lipid homeostasis and maintains stem cell enriched populations in AML
P430	Molecular characterization of clinical response in newly-diagnosed acute myeloid leukemia patients treated with ivosidenib + azacitidine compared to placebo + azacitidine
P470	NGS-based minimal residual disease detection in peripheral blood shows good prognostic value for OS and EFS in patients with acute myeloid leukemia recruited in the UNIFY trial
P498	Clinical and biological markers associated with long-term survival for patients with acute myeloid leukemia (AML) in remission after chemotherapy in the QUAZAR AML-001 trial of oral azacitidine
S130	NPM1 mutated AML: impact of co-mutational patterns - results of the European Harmony Alliance
S131	Clinical implications of secondary-AML type mutations in patients with de novo acute myeloid leukemia
S134	Intra-patient functional heterogeneity of AML determines first-line treatment response

Novel therapies

P510	The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia
P554	Gilteritinib versus salvage chemotherapy for relapsed/refractory FLT3-mutated acute myeloid leukemia: a phase 3, randomized, multicenter, open-label trial in Asia
P557	Hematologic improvements with ivosidenib + azacitidine compared with placebo + azacitidine in patients with newly-diagnosed acute myeloid leukemia
S100	Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML
S127	Quizartinib with decitabine and venetoclax (triplet) is active in patients with FLT3-ITD mutated acute myeloid leukemia - a phase I/II study
S132	Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: phase 1b results

Real-world data

P526

Real-world comparison of different treatment modalities for favorable risk acute myeloid leukemia: standard dose anthracycline vs high dose anthracycline vs addition of gemtuzumab ozogamicin

EHA2022 abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022

Your opinion matters

Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?

Subscribe to get the best content delivered to your inbox